Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Upstream Bio Inc (UPB)

Upstream Bio Inc (UPB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 436,635
  • Shares Outstanding, K 54,039
  • Annual Sales, $ 2,370 K
  • Annual Income, $ -62,810 K
  • EBIT $ -141 M
  • EBITDA $ -142 M
  • 60-Month Beta 1.90
  • Price/Sales 155.88
  • Price/Cash Flow N/A
  • Price/Book 1.22

Options Overview Details

View History
  • Implied Volatility 229.78% (+56.72%)
  • Historical Volatility 219.27%
  • IV Percentile 91%
  • IV Rank 61.35%
  • IV High 317.64% on 01/14/26
  • IV Low 90.32% on 11/19/25
  • Expected Move (DTE 26) 1.68 (20.83%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 180
  • Volume Avg (30-Day) 916
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 17,227
  • Open Int (30-Day) 10,116
  • Expected Range 6.40 to 9.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.73
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.90
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.93 +1.89%
on 02/18/26
32.83 -75.39%
on 01/27/26
-22.92 (-73.94%)
since 01/20/26
3-Month
7.93 +1.89%
on 02/18/26
33.68 -76.01%
on 01/14/26
-16.88 (-67.63%)
since 11/20/25
52-Week
5.14 +57.20%
on 04/09/25
33.68 -76.01%
on 01/14/26
-0.15 (-1.82%)
since 02/20/25

Most Recent Stories

More News
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also...

UPB : 8.08 (-5.39%)
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...

UPB : 8.08 (-5.39%)
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...

UPB : 8.08 (-5.39%)
Upstream Bio to Participate in Upcoming December Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...

UPB : 8.08 (-5.39%)
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints...

UPB : 8.08 (-5.39%)
Upstream Bio to Participate in Upcoming November Investor Conferences

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...

UPB : 8.08 (-5.39%)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS) and Upstream Bio, Inc. (UPB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merus (MRUS – Research Report) and Upstream Bio, Inc. (UPB – Research Report).Elevate Your Investing Strategy: Take...

UPB : 8.08 (-5.39%)
MRUS : 90.00 (-7.14%)
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed...

UPB : 8.08 (-5.39%)
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...

UPB : 8.08 (-5.39%)
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted...

UPB : 8.08 (-5.39%)

Business Summary

Upstream Bio Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development which targets the receptor for thymic stromal lymphopoietin,...

See More

Key Turning Points

3rd Resistance Point 9.19
2nd Resistance Point 8.94
1st Resistance Point 8.51
Last Price 8.08
1st Support Level 7.83
2nd Support Level 7.58
3rd Support Level 7.15

See More

52-Week High 33.68
Fibonacci 61.8% 22.78
Fibonacci 50% 19.41
Fibonacci 38.2% 16.04
Last Price 8.08
52-Week Low 5.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar